Baxter receives CE Mark approval for Vivia haemodialysis system

Baxter has announced that its new Vivia haemodialysis (HD) system has been granted European CE Mark approval.

The device is designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, which is known as High Dose HD therapy. As the patient is the primary operator, it features a touchscreen and a graphic user interface with large, easy-to-comprehend visuals and animations.

These attributes help to guide patients through setup, treatment and cleanup, while its Access Disconnect Sensor causes the system to stop pumping if the needle dislodges. It also includes one-button fluid infusion to help minimise user error and incorporates the Sharesource wireless connectivity platform.

Baxter will introduce Vivia in a limited number of European dialysis clinics in 2014, before expanding the rollout to more countries in 2015.

Dr Bruce Culleton, senior medical director at Baxter, said: "Vivia will allow a greater number of haemodialysis patients access to High Dose HD therapy in their home environment."

This comes after the company recently received EU approval for its new product Rixubis for use in the treatment of haemophilia B.